The two faces of IL-6 in the tumor microenvironment

Seminars in Immunology

Volumn 26, Issue 1, 2014, Pages 38-47

  Fisher, Daniel T ^a   Appenheimer, Michelle M ^a   Evans, Sharon S ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Adaptive tumor immunity; IL 6 trans signaling; T cell trafficking; Tumorigenesis

Indexed keywords

INTERLEUKIN 6;

ADAPTIVE IMMUNITY; CANCER CELL; CANCER EPIDEMIOLOGY; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; IMMUNE RESPONSE; LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ADAPTIVE TUMOR IMMUNITY; IL-6 TRANS-SIGNALING; T CELL TRAFFICKING; TUMORIGENESIS;

ADAPTIVE IMMUNITY; ANIMALS; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; CELLULAR MICROENVIRONMENT; HUMANS; INTERLEUKIN-6; LYMPH NODES; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; TUMOR MICROENVIRONMENT;

EID: 84896490235     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2014.01.008     Document Type: Review

References (86)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
2. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986, 315(26):1650-1659.
3. Coussens L.M., Zitvogel L., Palucka A.K. Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science 2013, 339(6117):286-291.
4. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454(7203):436-444.
5. Naugler W.E., Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008, 14(3):109-119.
6. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140(6):883-899.
7. Drews J. Paul Ehrlich: magister mundi. Nat Rev Drug Discov 2004, 3(9):797-801.
8. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331(6024):1565-1570.
9. Swartz M.A., Iida N., Roberts E.W., Sangaletti S., Wong M.H., Yull F.E., et al. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res 2012, 72(10):2473-2480.
10. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012, 12(4):253-268.
11. Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21(3):309-322.
12. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 2012, 8(9):1237-1247.
13. Gao S.P., Mark K.G., Leslie K., Pao W., Motoi N., Gerald W.L., et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007, 117(12):3846-3856.
14. Sansone P., Storci G., Tavolari S., Guarnieri T., Giovannini C., Taffurelli M., et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007, 117(12):3988-4002.
15. Angelo L.S., Talpaz M., Kurzrock R. Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53. Cancer Res 2002, 62(3):932-940.
16. Silver J.S., Hunter C.A. gp130 at the nexus of inflammation, autoimmunity, and cancer. J Leukoc Biol 2010, 88(6):1145-1156.
17. Fisher D.T., Chen Q., Skitzki J.J., Muhitch J.B., Zhou L., Appenheimer M.M., et al. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest 2011, 121(10):3846-3859.
18. Vardam T.D., Zhou L., Appenheimer M.M., Chen Q., Wang W.C., Baumann H., et al. Regulation of a lymphocyte-endothelial-IL-6 trans-signaling axis by fever-range thermal stress: hot spot of immune surveillance. Cytokine 2007, 39(1):84-96.
19. Jones S.A., Rose-John S. The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochim Biophys Acta 2002, 1592(3):251-263.
20. Hirano T., Ishihara K., Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000, 19(21):2548-2556.
21. Fischer M., Goldschmitt J., Peschel C., Brakenhoff J.P., Kallen K.J., Wollmer A., et al. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol 1997, 15(2):142-145.
22. Jostock T., Mullberg J., Ozbek S., Atreya R., Blinn G., Voltz N., et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001, 268(1):160-167.
23. Heikkila K., Ebrahim S., Lawlor D.A. Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur J Cancer 2008, 44(7):937-945.
24. Lippitz B.E. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013, 14(6):pe218-pe228.
25. Becker C., Fantini M.C., Schramm C., Lehr H.A., Wirtz S., Nikolaev A., et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004, 21(4):491-501.
26. Lesina M., Kurkowski M.U., Ludes K., Rose-John S., Treiber M., Kloppel G., et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011, 19(4):456-469.
27. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15(2):103-113.
28. Mantovani A., Sica A., Allavena P., Garlanda C., Locati M. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol 2009, 70(5):325-330.
29. Erez N., Truitt M., Olson P., Arron S.T., Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 2010, 17(2):135-147.
30. Oh K., Lee O.Y., Shon S.Y., Nam O., Ryu P.M., Seo M.W., et al. A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model. Breast Cancer Res 2013, 15(5):pR79.
31. Iliopoulos D., Hirsch H.A., Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009, 139(4):693-706.
32. Mitchem J.B., Brennan D.J., Knolhoff B.L., Belt B.A., Zhu Y., Sanford D.E., et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res 2013, 73(3):1128-1141.
33. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., et al. Stat3 as an oncogene. Cell 1999, 98(3):295-303.
34. Kiuchi N., Nakajima K., Ichiba M., Fukada T., Narimatsu M., Mizuno K., et al. STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med 1999, 189(1):63-73.
35. Rebouissou S., Amessou M., Couchy G., Poussin K., Imbeaud S., Pilati C., et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009, 457(7226):200-204.
36. Pilati C., Amessou M., Bihl M.P., Balabaud C., Nhieu J.T., Paradis V., et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med 2011, 208(7):1359-1366.
37. Thiem S., Pierce T.P., Palmieri M., Putoczki T.L., Buchert M., Preaudet A., et al. mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. J Clin Invest 2013, 123(2):767-781.
38. Barre B., Avril S., Coqueret O. Opposite regulation of myc and p21waf1 transcription by STAT3 proteins. J Biol Chem 2003, 278(5):2990-2996.
39. Gritsko T., Williams A., Turkson J., Kaneko S., Bowman T., Huang M., et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 2006, 12(1):11-19.
40. Hodge D.R., Peng B., Cherry J.C., Hurt E.M., Fox S.D., Kelley J.A., et al. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res 2005, 65(11):4673-4682.
41. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420(6917):860-867.
42. Xie T.X., Wei D., Liu M., Gao A.C., Ali-Osman F., Sawaya R., et al. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004, 23(20):3550-3560.
43. Wei L.H., Kuo M.L., Chen C.A., Chou C.H., Lai K.B., Lee C.N., et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003, 22(10):1517-1527.
44. Kim M.Y., Oskarsson T., Acharyya S., Nguyen D.X., Zhang X.H., Norton L., et al. Tumor self-seeding by circulating cancer cells. Cell 2009, 139(7):1315-1326.
45. Kujawski M., Kortylewski M., Lee H., Herrmann A., Kay H., Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 2008, 118(10):3367-3377.
46. Hanson E.M., Clements V.K., Sinha P., Ilkovitch D., Ostrand-Rosenberg S. Myeloid-derived suppressor cells down-regulate l-selectin expression on CD4+ and CD8+ T cells. J Immunol 2009, 183(2):937-944.
47. Chomarat P., Banchereau J., Davoust J., Palucka A.K. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 2000, 1(6):510-514.
48. Park S.J., Nakagawa T., Kitamura H., Atsumi T., Kamon H., Sawa S., et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 2004, 173(6):3844-3854.
49. Angell H., Galon J. From the immune contexture to the immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 2013, 25(2):261-267.
50. Fridman W.H., Pages F., Sautes-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012, 12(4):298-306.
51. Mikucki M.E., Fisher D.T., Ku A.W., Appenheimer M.M., Muhitch J.B., Evans S.S. Preconditioning thermal therapy: flipping the switch on IL-6 for anti-tumour immunity. Int J Hyperthermia 2013, 29(5):464-473.
52. Dejean A.S., Beisner D.R., Ch'en I.L., Kerdiles Y.M., Babour A., Arden K.C., et al. Transcription factor Foxo3 controls the magnitude of T cell immune responses by modulating the function of dendritic cells. Nat Immunol 2009, 10(5):504-513.
53. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 Cells. Annu Rev Immunol 2009, 27:485-517.
54. Dominitzki S., Fantini M.C., Neufert C., Nikolaev A., Galle P.R., Scheller J., et al. Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. J Immunol 2007, 179(4):2041-2045.
55. Appenheimer M.M., Girard R.A., Chen Q., Wang W.C., Bankert K.C., Hardison J., et al. Conservation of IL-6 trans-signaling mechanisms controlling l-selectin adhesion by fever-range thermal stress. Eur J Immunol 2007, 37(10):2856-2867.
56. Chen Q., Fisher D.T., Clancy K.A., Gauguet J.M., Wang W.C., Unger E., et al. Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism. Nat Immunol 2006, 7(12):1299-1308.
57. Chen Q., Wang W.C., Bruce R., Li H., Schleider D.M., Mulbury M.J., et al. Central role of IL-6 receptor signal-transducing chain gp130 in activation of l-selectin adhesion by fever-range thermal stress. Immunity 2004, 20(1):59-70.
58. Wang W.C., Goldman L.M., Schleider D.M., Appenheimer M.M., Subjeck J.R., Repasky E.A., et al. Fever-range hyperthermia enhances l-selectin-dependent adhesion of lymphocytes to vascular endothelium. J Immunol 1998, 160(2):961-969.
59. Evans S.S., Wang W.C., Bain M.D., Burd R., Ostberg J.R., Repasky E.A. Fever-range hyperthermia dynamically regulates lymphocyte delivery to high endothelial venules. Blood 2001, 97(9):2727-2733.
60. Kraybill W.G., Olenki T., Evans S.S., Ostberg J.R., O'Leary K.A., Gibbs J.F., et al. A phase I study of fever-range whole body hyperthermia (FR-WBH) in patients with advanced solid tumours: correlation with mouse models. Int J Hyperthermia 2002, 18(3):253-266.
61. Chen Q., Fisher D.T., Kucinska S.A., Wang W.C., Evans S.S. Dynamic control of lymphocyte trafficking by fever-range thermal stress. Cancer Immunol Immunother 2006, 55(3):299-311.
62. Chen Q., Appenheimer M.M., Muhitch J.B., Fisher D.T., Clancy K.A., Miecznikowski J.C., et al. Thermal facilitation of lymphocyte trafficking involves temporal induction of intravascular ICAM-1. Microcirculation 2009, 16(2):143-158.
63. Evans S.S., Bain M.D., Wang W.C. Fever-range hyperthermia stimulates alpha4beta7 integrin-dependent lymphocyte-endothelial adhesion. Int J Hyperthermia 2000, 16(1):45-59.
64. Evans S.S., Schleider D.M., Bowman L.A., Francis M.L., Kansas G.S., Black J.D. Dynamic association of l-selectin with the lymphocyte cytoskeletal matrix. J Immunol 1999, 162(6):3615-3624.
65. Romano M., Sironi M., Toniatti C., Polentarutti N., Fruscella P., Ghezzi P., et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997, 6(3):315-325.
66. Zitvogel L., Galluzzi L., Smyth M.J., Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013, 39(1):74-88.
67. Kroemer G., Galluzzi L., Kepp O., Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013, 31:51-72.
68. Bousso P., Robey E. Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nat Immunol 2003, 4(6):579-585.
69. Girard J.P., Moussion C., Forster R. HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat Rev Immunol 2012, 12(11):762-773.
70. Hope J.C., Cumberbatch M., Fielding I., Dearman R.J., Kimber I., Hopkins S.J. Identification of dendritic cells as a major source of interleukin-6 in draining lymph nodes following skin sensitization of mice. Immunology 1995, 86(3):441-447.
71. Leal I.S., Florido M., Andersen P., Appelberg R. Interleukin-6 regulates the phenotype of the immune response to a tuberculosis subunit vaccine. Immunology 2001, 103(3):375-381.
72. Eddahri F., Denanglaire S., Bureau F., Spolski R., Leonard W.J., Leo O., et al. Interleukin-6/STAT3 signaling regulates the ability of naive T cells to acquire B-cell help capacities. Blood 2009, 113(11):2426-2433.
73. Pasare C., Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003, 299(5609):1033-1036.
74. Sharma M.D., Hou D.Y., Baban B., Koni P.A., He Y., Chandler P.R., et al. Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity 2010, 33(6):942-954.
75. von Andrian U.H. Intravital microscopy of the peripheral lymph node microcirculation in mice. Microcirculation 1996, 3(3):287-300.
76. Repasky E.A., Evans S.S., Dewhirst M.W. Temperature matters! And why it should matter to tumor immunologists. Cancer Immunol Res 2013, 1(4):210-216.
77. Ostberg J.R., Taylor S.L., Baumann H., Repasky E.A. Regulatory effects of fever-range whole-body hyperthermia on the LPS-induced acute inflammatory response. J Leukoc Biol 2000, 68(6):815-820.
78. Jiang Q., DeTolla L., van Rooijen N., Singh I.S., Fitzgerald B., Lipsky M.M., et al. Febrile-range temperature modifies early systemic tumor necrosis factor alpha expression in mice challenged with bacterial endotoxin. Infect Immun 1999, 67(4):1539-1546.
79. Carriere V., Colisson R., Jiguet-Jiglaire C., Bellard E., Bouche G., Al Saati T., et al. Cancer cells regulate lymphocyte recruitment and leukocyte-endothelium interactions in the tumor-draining lymph node. Cancer Res 2005, 65(24):11639-11648.
80. Wu N.Z., Klitzman B., Dodge R., Dewhirst M.W. Diminished leukocyte-endothelium interaction in tumor microvessels. Cancer Res 1992, 52(15):4265-4268.
81. Melder R.J., Koenig G.C., Witwer B.P., Safabakhsh N., Munn L.L., Jain R.K. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 1996, 2(9):992-997.
82. Hellebrekers D.M., Castermans K., Vire E., Dings R.P., Hoebers N.T., Mayo K.H., et al. Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res 2006, 66(22):10770-10777.
83. Gajewski T.F., Schreiber H., Fu Y.X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013, 14(10):1014-1022.
84. Restifo N.P., Dudley M.E., Rosenberg S.A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012, 12(4):269-281.
85. Klouche M., Bhakdi S., Hemmes M., Rose-John S. Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J Immunol 1999, 163(8):4583-4589.
86. Letunic I., Bork P. Interactive Tree Of Life v2: online annotation and display of phylogenetic trees made easy. Nucleic Acids Res 2011, 39(Web Server issue):W475-W478.